ES2381452T3 - PIPERIDINO-DIHIDROTIENOPIRIMIDINAS sustituidas - Google Patents

PIPERIDINO-DIHIDROTIENOPIRIMIDINAS sustituidas Download PDF

Info

Publication number
ES2381452T3
ES2381452T3 ES08839793T ES08839793T ES2381452T3 ES 2381452 T3 ES2381452 T3 ES 2381452T3 ES 08839793 T ES08839793 T ES 08839793T ES 08839793 T ES08839793 T ES 08839793T ES 2381452 T3 ES2381452 T3 ES 2381452T3
Authority
ES
Spain
Prior art keywords
alkyl
alkylene
aryl
group
het
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08839793T
Other languages
English (en)
Inventor
Pascale Pouzet
Ralf; DOLLINGER Horst ANDERSKEWITZ
Dennis; FOX Thomas FIEGEN
Rolf; HOENKE Christoph GOEGGEL
Domnic; NICKOLAUS Peter MARTYRES
Klaus Klinder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39154006&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2381452(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Application granted granted Critical
Publication of ES2381452T3 publication Critical patent/ES2381452T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compuestos de fórmula 1, R3 en la cual X es SO o SO2; R1 es H, alquilo C1-6, R2 es H o un radical seleccionado del grupo consistente en alquilo C1-10 y alquenilo C2-6, que eventualmente puede estar sustituido con uno o varios radicales seleccionados de halógeno y fluoroalquilo C1-3 o que eventualmente puede estar sustituido con uno o varios radicales seleccionados del grupo que consiste en OROR2.1 SR2.1 SO2-R2.1, COOR2.1 , CONR2.2R2.3 , , SO-R2.1 , , arilo C6-10, -Het, Hetarilo, un cicloalquilo C3-10 monocíclico o bicíclico, CH2-NR2.2R2.3 y NR2.2R2.3 , que, de nuevo, puede estar eventualmente sustitudo con uno o varios radicales seleccionados del grupo consistente en OH, halógeno, OR2.1, oxo, CF3, CHF2, CH2F, alquilo C1-6, alcanol C1-6, arilo C6-10, COOR2.1 , CH2-NR2.2R2.3 y NR2.2R2.3 , en donde Het es un heterociclo de uno a once miembros, mono-o bi-cíclico, saturado o parcialmente saturado, eventualmente condensado o eventualmente puenteado, que contiene 1, 2, 3 ó 4 heteroátomos elegidos, independientemente uno de otro, del grupo consistente en N, S u O, y en donde Hetarilo es un heteroarilo de cinco a diez miembros, mono-o bi-cíclico, eventualmente condensado, que contiene 1, 2, 3 ó 4 heteroátomos seleccionados, independientemente uno de otro, del grupo consistente en N, S u O, y en donde cicloalquilo puede estar saturado o parcialmente saturado, en donde R2.1 es H o un radical seleccionado del grupo consistente en alquilo C1-6-, alcanol C1-6, haloalquilo C1-3, cicloalquilo C3-10 mono-o bi-cíclico, aril C6-10-alquileno C1-6, hetaril-alquileno C1-6, Het-alquileno C1-6, cicloalquil C3-10-alquileno C1-6, un arilo C6-10 mono-o bi-cíclico, heteroarilo y un -Het, que eventualmente puede estar sustituido con uno varios radicales seleccionados del grupo consistente en OH, O- (alquilo C1-3) , halógeno, alquilo C1-6 y arilo C6-10, y R2.3 en donde R2.2 son, de modo independiente entre sí, H o un radical que está seleccionado del grupo compuesto por alquilo C1-6, cicloalquilo C3-10 mono-o bicíclico, aril C6-10-alquileno C1-6, hetarilalquileno C1-6, arilo C6-10 mono-o bicíclico, Het, Hetarilo, CO-NH2, CO-NHCH3, CO-N (CH3) 2, SO2 (alquilo C1-C2) , CO-R2.1 y COOR2.1 , que eventualmente puede estar sustituido con uno o más radicales seleccionados del grupo consistente en OH, halógeno, alquilo C1-6, arilo C6-10 y COOR2.1 , o R2 es un cicloalquilo C3-10 mono-o policíclico que eventualmente puede estar puenteado una o varias veces a través de grupos alquilo C1-3 y que eventualmente puede estar sustituido con un radical seleccionado del grupo compuesto por alcanol C1-6 ramificado o no ramificado, fluoroalquilo C1-3, alquilen C1-3-OR2.1, OR2.1 , COOR2.1 , - SO2-NR2.2R2.3, Het, -NH-CO-O- (alquilo C1-6) , -NH-CO- (alquilo C1-6) , -NH-CO-O- (arilo C6-10) , -NH-CO- (arilo C6-10) , -NH-CO-O-Hetarilo, -NH-CO-Hetarilo, -NH-CO-O- (alquilen C1-3) - (arilo C6-10) , -NH-CO- (alquilen C1-3) (arilo C6-10) , -N (alquil C1-3) -CO- (alquilo C1-6) , -N (alquil C1-3) -CO-O- (arilo C6-10) , -N (alquil C1-3) -CO- (arilo C6-10) , - N (alquil C1-3) -CO-O-Hetarilo, -N (alquil C1-3) -CO-hetarilo, -N (alquil C1-3) -CO-O- (alquilen C1-3) - (arilo C6-10) , N (alquil C1-3) -CO- (alquilen C1-3) - (arilo C6-10) , arilo C6-10, alquilo C1-6, aril C6-10-alquileno C1-6, Hetaril-alquileno C1-6, cicloalquilo C3-10 mono-o bi-cíclcico y NR2.2R2.3 , que eventualmente puede estar sustituido con uno o varios radicales seleccionados del grupo compuesto por OH, OR2.1, oxo, halógeno, CF3, CHF2, CH2F, alquilo C1-6, arilo C6-10 y NR2.2R2.3 , o R2 es un arilo C6-10 mono-o poli-cíclico, que eventualmente puede estar sustituido con OH, SH o halógeno o OR2.1 NR2.2R2.3 con uno o varios radicales seleccionados del grupo consistente en , COOR2.1 , , CH2NR2.2R2.3, cicloalquilo C3-10, Het, alquilo C1-6, fluoroalquilo C1-3, CF3, CHF2, CH2F, aril C6-10-alquileno C1-6, Het-alquileno C1-6, Hetaril-alquileno C1-6, arilo C6-10, SO2-CH3, SO2-CH2CH3 y SO2-NR2.2R2.3 , que, de nuevo, puede estar eventualmente sustituido con uno o varios radicales seleccionados del grupo consistente en OH, OR2.1, CF3, CHF2, CH2F, oxo, halógeno, CF3, CHF2, CH2F, alquilo C1-6, arilo C6-10 y NR2.2R2.3 , o R2 es un radical seleccionado de un grupo consistente en Het y Hetarilo, que eventualmente puede estar sustituido con uno o varios radicales seleccionados del grupo halógeno, OH, oxo, CF3, CHF2 y CH2F o con uno o varios radicales seleccionados del grupo OR2.1, alquilen C1-3-OR2.1, SR2.1, SO-R2.1, SO2-R2.1, COOR2.1 , COR2.1, alcanol C1-6, cicloalqulo C3-10 mono-o bi-cíclico, arilo C6-10, alquilo C1-6, aril C6-10-alquileno C1-6, hetaril-alquileno C1-6, Het, Hetarilo, alquilen C1-3-OR2.1 y NR2.2R2.3 , que, de nuevo, eventualmente puede estar sustituido con uno o varios radicales seleccionados del grupo compuesto por OH, OR 2.1, oxo, halógeno, CF3, CHF2, CH2F, alquilo C1-6, arilo C6-10 y NR2.2R2.3 , o en donde NR1R2 son juntos un anillo heterocíclico C4-7 que eventualmente puede estar puentado, que contiene 1, 2 ó 3 heteroátomos seleccionados del grupo consistente en N, O y S y que eventualmente puede estar sustituido con uno o varios radicales seleccionados del grupo consistente en OH, OR2.1, alquilen C1-3-OR.1 , oxo, halógeno, alquilo C1-6, arilo C6-10, COOR2.1, CH2-NR2.2-COO-R2.1, CH2-NR2.2-CO-R2.1, CH2-NR2.2-CO-CH2 NR2.2R2.3 CH2-NR2.2-SO2-NR2.2R2.3 , CH2-NR2.2-SO2-alquilo C1-3, , CH2-NR2.2-CO-NR2.2R2.3 , CO-NR2.2R2.3 , CH2-NR2.2R2.3 y NR2.2R2.3 , y en donde R3 es un arilo C6-10, que, eventualmente, puede estar sustituido en posición orto, para o meta con uno, dos o tres radicales seleccionados, independientemente uno de otro, del grupo consistente en flúor, cloro, bromo, hidroxi, CN, alquilo C1-6, fluoroalquilo C1-3, -alquilen C1-3-OR2.1, -alquilen C1-3-NR2.2R2.3, -NR2.2R2.3, O-R2.1; SO-R2.1, SO2R2.1, COOR2.1 , -CO-NH- (alquilen C1-6) -Hetarilo, -CO-NH-Hetarilo, -CO-N (CH3) -Het, -CO-N (CH3) - (alquilen C1-3) -Het, -CO-N (CH3) - (alquilen C1-3) -Hetarilo, -CO-N (cicloalquil C3-7) -Het, -CO-NR2.2R2.3 , -CO-NH (alquilen C1-6) -Het, NR2.2-CO-R2.1, arilo C6-10, aril C6-10-alquileno C1-2, Het-alquileno C1-2, -Het, -CO-Het, CO-N (CH3) -cicloalquilo C3-7, cicloalquilo C3-7, cicloalquil C3-7-alquileno C1-2, Hetaril-alquileno C1-2 y Hetarilo, en donde este radical puede estar eventualmente sustituido con uno o varios radicales seleccionados del grupo consistente en OH, halógeno, -fluoroalquilo C1-3, oxo, metilo y fenilo, o en donde R3 es un radical seleccionado del grupo consistente en Het y Hetarilo, que eventualmente puede estar sustituido con uno o varios radicales seleccionados del grupo consistente en halógeno, fluoroalquilo C1-3, CN, OH, oxo, -alquilo C1-6, -alquilen C1-3-NR2.2R2.3 , -NR2.2R2.3, SO-R2.1, SO2-R2.1, -O-R2.1 , -COOR2.1, SO2 (CH3) , SO2- (CH2-CH3) , arilo C6-10, Het, cicloalquilo C3-7 y Hetarilo, que, de nuevo, eventualmente puede estar sustituido con uno o varios radicales seleccionados del grupo consistente en OH, halógeno, -fluoroalquilo C1-3, alquilo C1-6, arilo C6-10, -COO (alquilo C1-3) y O- (alquilo C1-3) , o en donde R3 es -O-R3.1 , en donde R3.1 es un radical seleccionado del grupo consistente en -alquilo C1-6, -arilo C6-10, -alquilen C1-3-arilo C6-10, Hetarilo y Het, que, eventualmente puede estar sustituido, en posición orto, para o meta, con uno, dos o tres radicales seleccionados, independientemente uno de otro, del grupo consistente en flúor, cloro, bromo, hidroxi, CN, alquilo C1-6, fluoroalquilo C1-3, CO- (alquilo C1-5) , -CO- (fluoroalquilo C1-3) , -CONH- (alquilen C1-6) -Hetarilo, -CO-N (alquil C1-3) - (alquilen C1-6) -Hetarilo, -CO-N (alquil C1-3) -Het, -CO-N (cicloalquil C3-7) -Het, -alquilen C1-3-OR2.1 , -alquilen C1-3-NR2.2R2.3, -NR2.2R2.3, O-R2.1; SO-R2.1, SO2-R2.1, COOH, COO- (alquilo C1-4) , -O-alquilen C1-3-N (alquilo C1-3) 2, CO-NR2.2R2.3, NR2.2-CO-R2.1 , arilo C6-10, aril C6-10-alquileno C1-2, Het-alquileno C1-2, -CO-Het, Het, -CO-cicloalquilo C3-7, -CO-N (alquil C1-3) -cicloalquilo C3-7, ciloalquilo C3-7, ciloalquil C3-7-alquileno C1-2, Hetaril-alquileno C1-2 y Hetarilo, que, de nuevo, eventualmente puede estar sustituido con 1, 2, 3 ó 4 radicales seleccionados, independientemente uno de otro, del grupo consistente en F, Cl, Br, metilo, O-metilo, etilo, O-etilo, OH, oxo y CF3. y en donde R4 es H, CN, OH, CF3, CHF2, CH2F, F, metilo, etilo, -O- (alquilo C1-3) , -alquilen C1-3-OH, -COO (alquilo C1-3) , -CO-Het, - (alquilen C1-2) -NH-SO2- (alquilo C1-2) , - (alquilen C1-2) -N (alquil C1-3) -SO2- (alquilo C1-2) , - (alquilen C1-2) -O- (alquilen C1-2) -arilo C6-10, -alquilen C1-3-O-alquilo C1-3, - (alquilen C1-2) -N (alquil C1-3) -CO- (alquilo C1-2) , -NH-CO- (alquilen C1-3) -O- (alquilo C1-3) , -alquilen C1-3-NH-CO- (alquilo C1-3) , -alquilen C1-3-NH-CO- (alquilen C1-3) -N (alquilo C1-3) 2, -O- (alquilen C1-2) - (arilo C6-10) , -alquilen C1-3-NH-CO- (alquilen C1-3) -O- (alquilo C1-3) , -CO- (arilo C6-10) , - (alquilen C1-2) -N (alquil C1-3) -CO- (alquilen C1-2) -O- (alquilo C1-3) , en donde el arilo en los radicales anteriores puede estar sustituido, eventualmente de nuevo, con uno o varios otros radicales seleccionados del grupo F, Cl, Br, metilo, etilo, propilo, isopropilo, ciclopropilo, -Ometilo, -O-etilo, -O-propilo, -O-isopropilo, -O-ciclopropilo, -OH y CF3 , o en donde R3 y R4 , en común, forman un heterociclo mono-o bi-cíclico insaturado, saturado o parcialmente saturado, que contiene 1, 2 ó 3 heteroátomos seleccionados del grupo consistente en N, O y S y que, eventualmente, puede estar sustituido con uno o varios radicales seleccionados del grupo consistente en halógeno, OH, oxo, fluoroalquilo C1-3, CN, alquilo C1-6, -O-R2.1 , -COOR2.1, SO-R2.1, SO2-R2.1, -alquilen C1-3-NR2.2R2.3 , NR2.2R2.3, arilo C6-10, cicloalquilo C3-7, Het y Hetarilo, así como sales farmacológicamente compatibles de los mismos.
ES08839793T 2007-10-19 2008-10-16 PIPERIDINO-DIHIDROTIENOPIRIMIDINAS sustituidas Active ES2381452T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07118901 2007-10-19
EP07118901 2007-10-19
PCT/EP2008/063999 WO2009050248A1 (de) 2007-10-19 2008-10-16 Substituierte piperidino-dihydrothienopyrimidine

Publications (1)

Publication Number Publication Date
ES2381452T3 true ES2381452T3 (es) 2012-05-28

Family

ID=39154006

Family Applications (2)

Application Number Title Priority Date Filing Date
ES08839793T Active ES2381452T3 (es) 2007-10-19 2008-10-16 PIPERIDINO-DIHIDROTIENOPIRIMIDINAS sustituidas
ES13154790.3T Active ES2524910T3 (es) 2007-10-19 2008-10-16 Piperidino-dihidrotienopirimidinas sustituidas

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES13154790.3T Active ES2524910T3 (es) 2007-10-19 2008-10-16 Piperidino-dihidrotienopirimidinas sustituidas

Country Status (34)

Country Link
US (1) US8754073B2 (es)
EP (3) EP2215092B1 (es)
JP (2) JP5150728B2 (es)
KR (1) KR101548975B1 (es)
CN (2) CN104069112A (es)
AR (1) AR069075A1 (es)
AT (1) ATE542825T1 (es)
AU (1) AU2008313660B2 (es)
BR (1) BRPI0818006B8 (es)
CA (1) CA2705414C (es)
CL (1) CL2008003096A1 (es)
CY (2) CY1112703T1 (es)
DK (2) DK2610258T3 (es)
EA (1) EA019480B1 (es)
EC (1) ECSP10010156A (es)
ES (2) ES2381452T3 (es)
HK (1) HK1145677A1 (es)
HR (2) HRP20120334T1 (es)
MA (1) MA31845B1 (es)
ME (1) ME01330B (es)
MX (1) MX2010004026A (es)
MY (1) MY153979A (es)
NZ (1) NZ585346A (es)
PE (2) PE20131463A1 (es)
PL (2) PL2215092T3 (es)
PT (2) PT2215092E (es)
RS (1) RS52271B (es)
SI (2) SI2610258T1 (es)
TN (1) TN2010000175A1 (es)
TW (1) TWI421077B (es)
UA (1) UA99309C2 (es)
UY (1) UY31405A1 (es)
WO (1) WO2009050248A1 (es)
ZA (1) ZA201001683B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1847543A1 (de) 2006-04-19 2007-10-24 Boehringer Ingelheim Pharma GmbH & Co. KG Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen
NZ592534A (en) * 2007-10-18 2013-03-28 Boehringer Ingelheim Int Preparation of dihydrothieno [3,2-D] pyrimidines and intermediates used therein
EP2205609B1 (de) 2007-10-19 2017-03-29 Boehringer Ingelheim International GmbH Heterocyclus-substituierte piperazino-dihydrothienopyrimidine
CA2702518A1 (en) 2007-10-19 2009-04-23 Boehringer Ingelheim International Gmbh New piperazino-dihydrothienopyrimidine derivatives
WO2009050248A1 (de) * 2007-10-19 2009-04-23 Boehringer Ingelheim International Gmbh Substituierte piperidino-dihydrothienopyrimidine
US9161927B2 (en) 2009-02-27 2015-10-20 Boehringer Ingelheim International Gmbh Drug combinations containing PDE4 inhibitors and NSAIDs
WO2011124524A1 (de) 2010-04-08 2011-10-13 Boehringer Ingelheim International Gmbh Arzneimittelkombinationen enthaltend pde4-inhibitoren und ep4-rezeptor-antagonisten
EP2555774B1 (de) 2010-04-08 2015-10-21 Boehringer Ingelheim International GmbH Arnzeimittelkombinationen enthaltend pde4-inhibitoren und ep4-rezeptor-antagonisten
EP2568812B1 (en) * 2010-05-11 2016-10-26 Merck Sharp & Dohme Corp. Novel prolylcarboxypeptidase inhibitors
US20130059866A1 (en) 2011-08-24 2013-03-07 Boehringer Ingelheim International Gmbh Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma
US9802954B2 (en) 2011-08-24 2017-10-31 Boehringer Ingelheim International Gmbh Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma
US9013997B2 (en) * 2012-06-01 2015-04-21 Broadcom Corporation System for performing distributed data cut-through
US9499519B2 (en) 2012-12-26 2016-11-22 Medivation Technologies, Inc. Fused pyrimidine compounds and use thereof
CA2899963A1 (en) * 2013-02-04 2014-08-07 Grunenthal Gmbh Novel substituted condensed pyrimidine compounds
WO2014124860A1 (en) 2013-02-14 2014-08-21 Boehringer Ingelheim International Gmbh Specific pde4b-inhibitors for the treatment of diabetes mellitus
HUP1300139A2 (en) * 2013-03-06 2014-09-29 Richter Gedeon Nyrt Phenoxypiperidine h3 antagonists
CN104892720B (zh) * 2014-03-07 2016-10-26 华东师范大学 4,4-二甲基石胆酸-2,3-骈n-芳基吡唑衍生物及其制备方法和应用
NZ749946A (en) * 2016-06-30 2023-11-24 Yakult Honsha Kk Novel compound or pharmaceutically acceptable salt thereof
WO2019057806A1 (en) 2017-09-20 2019-03-28 Leo Pharma A/S SUBSTITUTED DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS
CN111278442B (zh) 2017-10-23 2023-06-06 勃林格殷格翰国际有限公司 用于治疗进行性纤维化间质性肺病(pf-ild)的活性剂的新组合
WO2019115774A1 (en) 2017-12-15 2019-06-20 Leo Pharma A/S Substituted azetidine dihydrothienopyrimidines and their use as phosphodiesterase inhibitors
WO2019115775A1 (en) 2017-12-15 2019-06-20 Leo Pharma A/S Substituted tetrahydropyran dihydrothienopyrimidines and their use as phosphodiesterase inhibitors
FI3724196T3 (fi) 2017-12-15 2023-01-31 Substituoituja atsetidiinidihydrotienopyridiinejä ja niiden käyttö fosfodiesteraasin estäjinä
WO2020048827A1 (en) * 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 1, 3, 9-triazaspiro[5.5] undecan-2-one compounds
TW202339731A (zh) 2021-12-09 2023-10-16 德商百靈佳殷格翰國際股份有限公司 用於治療進行性纖維化間質性肺病之新穎口服醫藥組合物及劑量療法
US20230190754A1 (en) 2021-12-09 2023-06-22 Boehringer Ingelheim International Gmbh Therapeutic combinations for the treatment of Progressive Fibrosing interstitial lung diseases
WO2023232135A1 (zh) * 2022-06-02 2023-12-07 西藏海思科制药有限公司 Pde4b抑制剂及其用途
CN117247395A (zh) * 2022-06-16 2023-12-19 武汉人福创新药物研发中心有限公司 Pde4b抑制剂
CN115040503B (zh) * 2022-07-26 2023-10-10 云南民族大学 螺环二烯酮型木脂素类化合物在制药中的应用
WO2024032673A1 (zh) * 2022-08-09 2024-02-15 西藏海思科制药有限公司 Pde4b抑制剂及其用途
WO2024068386A1 (en) 2022-09-28 2024-04-04 Boehringer Ingelheim International Gmbh Use of biomarkers in the treatment of fibrotic conditions with a pde4b-inhibitor
WO2024067660A1 (zh) * 2022-09-29 2024-04-04 苏州爱科百发生物医药技术有限公司 氮杂稠环类化合物、其制备方法及其在医药上的应用
WO2024179493A1 (zh) * 2023-02-28 2024-09-06 上海翊石医药科技有限公司 二氢噻吩并嘧啶衍生物的制备方法和用途
WO2024208225A1 (zh) * 2023-04-03 2024-10-10 上海壹迪生物技术有限公司 二氢噻吩并嘧啶类化合物、其制备方法和应用

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1470336A1 (de) 1962-07-04 1969-03-20 Thomae Gmbh Dr K Neue Dihydrothieno-[3,4-d]-pyrimidine und Verfahren zu ihrer Herstellung
NL122810C (es) 1963-06-17
DE1470356A1 (de) 1964-01-15 1970-04-30 Thomae Gmbh Dr K Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
BE663693A (es) 1965-03-31
DE1940572A1 (de) 1969-08-08 1971-02-11 Thomae Gmbh Dr K Neue 2-Aminoalkylamino-thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
BE754606A (fr) * 1969-08-08 1971-02-08 Thomae Gmbh Dr K Nouvelles 2-aminoalcoylamino-thieno(3,2-d)pyrimidines et leurs procedesde fabrication
DE2032687A1 (en) 1970-07-02 1972-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Cardiovascular 2-aminoalkylamino-thienopyrimidines - and 4-morpholino derivatives from 4-diethanolamino-compounds by intramolecular cyclisa
US3763156A (en) * 1970-01-28 1973-10-02 Boehringer Sohn Ingelheim 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines
FR2082496A5 (es) 1970-03-18 1971-12-10 Westinghouse Freins & Signaux
DE2121950A1 (en) 1971-05-04 1972-11-23 Dr. Karl Thomae Gmbh, 7950 Biberach Thieno(3,2-d)pyrimidine derivs - with thrombocyte aggregation inhibiting activity
DE2750288A1 (de) * 1977-11-10 1979-05-17 Thomae Gmbh Dr K Neue 9-(omega-heteroarylamino- alkylamino)-erythromycine, ihre salze, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
US4256737A (en) * 1979-06-11 1981-03-17 Syntex (U.S.A.) Inc. Long acting depot injectable formulations for LH-RH analogues
US5187168A (en) * 1991-10-24 1993-02-16 American Home Products Corporation Substituted quinazolines as angiotensin II antagonists
US5491201A (en) 1992-02-06 1996-02-13 The Dow Chemical Company Mesogenic cyclic imino ether-containing compositions and polymerization products thereof
JPH07330777A (ja) 1994-06-08 1995-12-19 Taisho Pharmaceut Co Ltd チエノ［３，２−ｄ］ピリミジン−４−オン誘導体
JPH09301958A (ja) 1996-05-09 1997-11-25 Nippon Shoji Kk 新規ピリミジン化合物及び抗ロタウイルス剤
US6339089B2 (en) 1997-08-13 2002-01-15 Fujirebio Inc. Pyrimidine nucleus-containing compound and a medicament containing the same for a blood oxygen partial pressure amelioration, and a method for preparing the same
AU2001229501A1 (en) 2000-01-24 2001-07-31 Isis Pharmaceuticals, Inc. Antisense modulation of inducible nitric oxide synthase expression
GB0004153D0 (en) 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel use
CZ301841B6 (cs) 2000-10-12 2010-07-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Krystalický monohydrát tiotropiumbromidu, zpusob jeho výroby a jeho použití pro výrobu léciva
DE10064994A1 (de) * 2000-12-23 2002-07-04 Merck Patent Gmbh Sulfamidothienopyrimidine
CN100343258C (zh) 2001-04-30 2007-10-17 美国拜尔公司 新的4－氨基－5,6－取代的噻吩并[2,3－d]嘧啶化合物
AR035700A1 (es) 2001-05-08 2004-06-23 Astrazeneca Ab Derivados de arilheteroalquilamina, composicion farmaceutica, usos de estos derivados para la fabricacion de medicamentos, metodos de tratamiento, y proceso para la preparacion de estos derivados
KR100971616B1 (ko) 2001-06-22 2010-07-22 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 결정질 항콜린제, 이의 제조방법 및 이를 포함하는 약제학적 조성물
US6587548B2 (en) * 2001-07-17 2003-07-01 Hewlett-Packard Development Co., L.P. Method and system of using a single telephone number for multiple services
AU2002364211A1 (en) 2001-12-21 2003-07-15 Bayer Pharmaceuticals Corporation Thienopyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
AU2003202263A1 (en) 2002-01-10 2003-07-30 Bayer Healthcare Ag Roh-kinase inhibitors
SE0203304D0 (sv) 2002-11-07 2002-11-07 Astrazeneca Ab Novel Coumpounds
AU2004234158B2 (en) 2003-04-29 2010-01-28 Pfizer Inc. 5,7-diaminopyrazolo[4,3-D]pyrimidines useful in the treatment of hypertension
US20050084878A1 (en) 2003-05-16 2005-04-21 Wisconsin Alumni Research Foundation Method for isolating and cloning high molecular weight polynucleotide molecules from the environment
JP2005003345A (ja) 2003-05-21 2005-01-06 Showa Denko Kk 換気兼熱交換装置および空調システム
JP4733043B2 (ja) * 2003-10-02 2011-07-27 マーテック バイオサイエンシーズ コーポレーション 改変された量の塩化物およびカリウムを使用した微細藻類における高レベルのｄｈａの産生法
MY141220A (en) 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
US20050137186A1 (en) 2003-12-18 2005-06-23 Abbott Gmbh & Co. Kg. Tetrahydrobenzazepines and their use
ATE457309T1 (de) 2003-12-23 2010-02-15 Serodus As Modulatoren von peripheren 5-ht-rezeptoren
WO2005082865A1 (ja) 2004-02-27 2005-09-09 Astellas Pharma Inc. 縮合二環性ピリミジン誘導体
GB0427403D0 (en) 2004-12-15 2005-01-19 Astrazeneca Ab Novel compounds I
WO2006111549A1 (de) * 2005-04-21 2006-10-26 Boehringer Ingelheim International Gmbh Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
KR20080005601A (ko) 2005-05-11 2008-01-14 니코메드 게엠베하 Ｐｄｅ４ 억제제 로플루밀라스트와 테트라히드로비오프테린유도체의 조합
EP1847543A1 (de) * 2006-04-19 2007-10-24 Boehringer Ingelheim Pharma GmbH & Co. KG Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen
MY149347A (en) 2007-04-20 2013-08-30 Glaxo Group Ltd Tricyclic nitrogen containing compounds as antibacterial agents
NZ592534A (en) 2007-10-18 2013-03-28 Boehringer Ingelheim Int Preparation of dihydrothieno [3,2-D] pyrimidines and intermediates used therein
BRPI0818605A2 (pt) * 2007-10-19 2015-04-22 Schering Corp Derivados de 1,3,4-tiadiazl espiro-condensados para inibir a atividade de ksp cinesima
CA2702518A1 (en) 2007-10-19 2009-04-23 Boehringer Ingelheim International Gmbh New piperazino-dihydrothienopyrimidine derivatives
EP2205609B1 (de) 2007-10-19 2017-03-29 Boehringer Ingelheim International GmbH Heterocyclus-substituierte piperazino-dihydrothienopyrimidine
FR2922550B1 (fr) 2007-10-19 2009-11-27 Sanofi Aventis Nouveaux derives de 6-aryl/heteroalkyloxy benzothiazole et benzimidazole, application comme medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de cmet
WO2009051556A1 (en) * 2007-10-19 2009-04-23 Astrazeneca Ab Tetrazole derivatives as modulators of metabotropic glutamate receptors (mglurs)
WO2009050248A1 (de) * 2007-10-19 2009-04-23 Boehringer Ingelheim International Gmbh Substituierte piperidino-dihydrothienopyrimidine
CA2702447A1 (en) * 2007-10-19 2009-04-30 Boehringer Ingelheim International Gmbh New phenyl-substituted piperazino-dihydrothienopyrimidines
US9161927B2 (en) * 2009-02-27 2015-10-20 Boehringer Ingelheim International Gmbh Drug combinations containing PDE4 inhibitors and NSAIDs
CA2753597A1 (en) 2009-02-27 2010-09-02 Boehringer Ingelheim International Gmbh Drug combinations containing pde4-inhibitors and nsaids
US20130059866A1 (en) * 2011-08-24 2013-03-07 Boehringer Ingelheim International Gmbh Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma

Also Published As

Publication number Publication date
ZA201001683B (en) 2010-10-27
UY31405A1 (es) 2009-05-29
NZ585346A (en) 2011-09-30
PE20091386A1 (es) 2009-10-17
PL2215092T3 (pl) 2012-07-31
EP2215092B1 (de) 2012-01-25
ME01330B (me) 2013-12-20
EA201000609A1 (ru) 2010-10-29
AU2008313660A1 (en) 2009-04-23
ATE542825T1 (de) 2012-02-15
MA31845B1 (fr) 2010-11-01
PT2215092E (pt) 2012-04-10
UA99309C2 (ru) 2012-08-10
JP2011500640A (ja) 2011-01-06
CY1115858T1 (el) 2017-01-25
BRPI0818006B8 (pt) 2021-05-25
TW200918074A (en) 2009-05-01
HK1145677A1 (en) 2011-04-29
DK2215092T3 (da) 2012-05-07
AU2008313660B2 (en) 2013-11-07
SI2215092T1 (sl) 2012-04-30
JP5615889B2 (ja) 2014-10-29
MY153979A (en) 2015-04-30
EP2215092A1 (de) 2010-08-11
CN101827852A (zh) 2010-09-08
JP2013064001A (ja) 2013-04-11
DK2610258T3 (da) 2014-11-10
MX2010004026A (es) 2010-04-30
RS52271B (en) 2012-10-31
KR20100100807A (ko) 2010-09-15
HRP20141153T1 (hr) 2015-02-13
TWI421077B (zh) 2014-01-01
CN101827852B (zh) 2014-07-30
EP2610258A1 (de) 2013-07-03
EP2380891B1 (de) 2013-12-11
TN2010000175A1 (fr) 2011-11-11
ES2524910T3 (es) 2014-12-15
EA019480B1 (ru) 2014-04-30
CL2008003096A1 (es) 2010-02-12
PT2610258E (pt) 2014-10-24
PL2610258T3 (pl) 2015-02-27
EP2380891A1 (de) 2011-10-26
PE20131463A1 (es) 2013-12-23
HRP20120334T1 (hr) 2012-05-31
WO2009050248A1 (de) 2009-04-23
CY1112703T1 (el) 2016-02-10
CN104069112A (zh) 2014-10-01
US20110021501A1 (en) 2011-01-27
EP2610258B1 (de) 2014-08-27
ECSP10010156A (es) 2010-06-29
BRPI0818006B1 (pt) 2019-10-22
US8754073B2 (en) 2014-06-17
CA2705414C (en) 2016-05-24
KR101548975B1 (ko) 2015-09-01
SI2610258T1 (sl) 2014-12-31
CA2705414A1 (en) 2009-04-23
BRPI0818006A2 (pt) 2015-12-22
AR069075A1 (es) 2009-12-30
JP5150728B2 (ja) 2013-02-27

Similar Documents

Publication Publication Date Title
ES2381452T3 (es) PIPERIDINO-DIHIDROTIENOPIRIMIDINAS sustituidas
AR060266A1 (es) Tiazolil - dihidro - indazoles
AR075594A1 (es) Derivados de ( 2-tienil)-sulfonil-amino-1h-indazol como antagonistas de ccr4
PE20150350A1 (es) Acidos 5-aminotetrahidroquinolin-2-carboxilicos novedosos y su uso
AR066799A1 (es) Antagonistas para el receptor ccr2 y sus usos
AR082946A1 (es) Imidazopiridazinas sustituidas
AR083876A1 (es) 5-halogenopirazolcarboxamidas
AR070224A1 (es) Inhibidores de proteina quinasa y uso de los mismos
AR050932A1 (es) Amidas biciclicas como inhibidores de cinasa
AR050610A1 (es) Derivados de dihidropteridinona
AR051921A1 (es) Acidos sustituidos utiles como compuestos farmaceuticos para tratar trastornos respiratorios, composiciones farmaceuticas que los contienen, y procesos para su preparacion
AR083398A1 (es) Compuestos antivirales
AR065874A1 (es) Compuestos de pirimidina hidrazida como inhibidores de pgds
AR078535A1 (es) Derivados de pirrolo[2,3-b]piridina ligandos de receptores estrogenicos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de la osteoporosis y enfermedades del sistema nervioso central, entre otras
AR090044A1 (es) Agentes antivirales para la hepatitis b
AR083542A1 (es) Piperidin-4-il-azetidin diamidas como inhibidores de monoacilglicerol lipasa
AR082004A1 (es) Compuestos de fusion de piridina
AR079015A1 (es) Acidos 3-fenilpropionicos sustituidos, metodo de preparacion y uso de los mismos
ES2600636T3 (es) Spiro-[1,3]-oxazinas y spiro-[1,4]-oxazepinas como inhibidores de BACE1 y/o BACE2
AR049186A1 (es) Derivados de oxazol como moduladores de ppar
AR076360A1 (es) Derivados de 3,3'-espiroindolinona y su uso en el tratamiento del cancer
AR086837A1 (es) Moduladores heterociclicos de sintesis lipidica
AR083058A1 (es) Compuestos de estructura de imidazotriazinona
AR060516A1 (es) Dihidrotienopirimidinas utilizables en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de pde4 y composiciones farmaceuticas que las contienen.
AR080955A1 (es) Aril-/heteroaril-ciclohexenil-tetraazabenzo(e)azulenos